New insight in the pathobiology of hepatitis B virus infection

Gut

Volumn 61, Issue SUPPL. 1, 2012, Pages

  Dandri, Maura ^a   Locarnini, Stephen ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; CIRCULAR DNA; DOUBLE STRANDED DNA; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; RIBAVIRIN; VIRUS DNA;

ADAPTIVE IMMUNITY; ANTIBODY BLOOD LEVEL; ANTIGEN BLOOD LEVEL; BLOOD LEVEL; CANCER RISK; CELLULAR IMMUNITY; DECOMPENSATED LIVER CIRRHOSIS; DELTA AGENT HEPATITIS; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; DNA METHYLATION; DNA TRANSCRIPTION; ERADICATION THERAPY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFECTION CONTROL; INNATE IMMUNITY; LIVER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; MEDICAL RESEARCH; MIXED INFECTION; NONHUMAN; PERSISTENT INFECTION; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SEROCONVERSION; SEROLOGY; TREATMENT RESPONSE; VIROLOGY; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS REACTIVATION; VIRUS REPLICATION;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; IMMUNITY, INNATE; VIRUS REPLICATION;

EID: 84860337613     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302056     Document Type: Review

References (122)

1. Block TM, Guo H, Guo JT. Molecular virology of hepatitis B virus for clinicians. Clin Liver Dis 2007;11:685-706, vii. (Pubitemid 350019022)
2. Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004;127:S303-9. (Pubitemid 39423400)
3. Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis 2011;32:1122-32.
4. Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 2009;286:52-9.
5. Glebe D, Urban S. Viral and cellular determinants involved in hepadnaviral entry. World J Gastroenterol 2007;13:22-38. (Pubitemid 46165460)
6. Levrero M, Pollicino T, Petersen J, et al. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009;51:581-92.
7. Zoulim F, Saputelli J, Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol 1994;68:2026-30. (Pubitemid 24065779)
8. Lucifora J, Arzberger S, Durantel D, et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 2011;55:996-1003.
9. Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res 2008;134:235-49.
10. Norder H, Courouce AM, Magnius LO. Molecular basis of hepatitis B virus serotype variations within the four major subtypes. J Gen Virol 1992;73:3141-5. (Pubitemid 23014164)
11. Garcia PD, Ou JH, Rutter WJ, et al. Targeting of the hepatitis B virus precore protein to the endoplasmic reticulum membrane: after signal peptide cleavage translocation can be aborted and the product released into the cytoplasm. J Cell Biol 1988;106:1093-104.
12. Lang T, Lo C, Skinner N, et al. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol 2011;55:762-9.
13. Revill P, Yuen L, Walsh R, et al. Bioinformatic analysis of the hepadnavirus e-antigen and its precursor identifies remarkable sequence conservation in all orthohepadnaviruses. J Med Virol 2010;82:104-15.
14. Urban S, Schulze A, Dandri M, et al. The replication cycle of hepatitis B virus. J Hepatol 2010;52:282-4.
15. Schmitz A, Schwarz A, Foss M, et al. Nucleoporin 153 arrests the nuclear import of hepatitis B virus capsids in the nuclear basket. PLoS Pathog 2010;6:e1000741.
16. Newbold JE, Xin H, Tencza M, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 1995;69:3350-7.
17. Dandri M, Burda MR, Burkle A, et al. Increase in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly(ADP-ribosyl)ation. Hepatology 2002;35:217-23. (Pubitemid 34032563)
18. Petersen J, Dandri M, Gupta S, et al. Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1998;95:310-15. (Pubitemid 28103950)
19. Mason WS, Jilbert AR, Summers J. Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. Proc Natl Acad Sci U S A 2005;102:1139-44. (Pubitemid 40170739)
20. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005;42:302-8. (Pubitemid 40254242)
21. Zhang YY, Zhang BH, Theele D, et al. Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver. Proc Natl Acad Sci U S A 2003;100:12372-7. (Pubitemid 37271567)
22. Dandri M, Burda MR, Will H, et al. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology 2000;32:139-46. (Pubitemid 30432379)
23. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-8. (Pubitemid 38736340)
24. Wong DK, Yuen MF, Yuan H, et al. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 2004;40:727-37. (Pubitemid 39265596)
25. Laras A, Koskinas J, Dimou E, et al. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 2006;44:694-702. (Pubitemid 44433726)
26. Volz T, Lutgehetmann M, Wachtler P, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 2007;133:843-52. (Pubitemid 47374140)
27. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675-84. (Pubitemid 44433724)
28. Lutgehetmann M, Volzt T, Quaas A, et al. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther 2008;13:57-66. (Pubitemid 351541674)
29. Petersen J, Dandri M, Mier W, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008;26:335-41. (Pubitemid 351355128)
30. Lutgehetmann M, Bornscheuer T, Volz T, et al. Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice. Gastroenterology 2011;140:2074-83.
31. Lutgehetmann M, Mancke LV, Volz T, et al. Human chimeric uPA mouse model to study hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology 2012;55:685-94.
32. Lutgehetmann M, Volz T, Kopke A, et al. In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology 2010;52:16-24.
33. Kock J, Rosler C, Zhang JJ, et al. Generation of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner. PLoS Pathog 2010;6:e1001082.
34. Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol 2007;13:48-64. (Pubitemid 46165462)
35. Lentz TB, Loeb DD. Roles of the envelope proteins in the amplification of covalently closed circular DNA and completion of synthesis of the plus-strand DNA in hepatitis B virus. J Virol 2011;85:11916-27.
36. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
37. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigennegative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006;26:130-41. (Pubitemid 43668255)
38. Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int. Published Online First: 18 September 2009. doi:10.1007/s12072-009-9149-7
39. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010;52:514-22.
40. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010;139:483-90.
41. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002;36:1408-15. (Pubitemid 35407438)
42. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7. (Pubitemid 26157437)
43. Chen YC, Sheen IS, Chu CM, et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002;123:1084-9.
44. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-52.
45. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582-92.
46. Pawlotsky JM. Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis 2003;7:45-66.
47. da Silva J. The evolutionary adaptation of HIV-1 to specific immunity. Curr HIV Res 2003;1:363-71.
48. Lim SG, Cheng Y, Guindon S, et al. Viral quasi-species evolution during hepatitis Be antigen seroconversion. Gastroenterology 2007;133:951-8. (Pubitemid 47381357)
49. Bozkaya H, Ayola B, Lok AS. High rate of mutations in the hepatitis B core gene during the immune clearance phase of chronic hepatitis B virus infection. Hepatology 1996;24:32-7. (Pubitemid 26249409)
50. Raimondo G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection. J Hepatol 2007;46:160-70. (Pubitemid 44827430)
51. Zerbini A, Pilli M, Boni C, et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008;134:1470-81. (Pubitemid 351615362)
52. Bowden S. Serological and molecular diagnosis. Semin Liver Dis 2006;26:97-103. (Pubitemid 43668252)
53. Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 2008;48:1001-26. (Pubitemid 351614923)
54. Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008;47:428-34. (Pubitemid 351280710)
55. Maruyama T, McLachlan A, Iino S, et al. The serology of chronic hepatitis B infection revisited. J Clin Invest 1993;91:2586-95. (Pubitemid 23182513)
56. Nguyen T, Locarnini S. Hepatitis: monitoring drug therapy for hepatitis B - a global challenge? Nat Rev Gastroenterol Hepatol 2009;6:565-7.
57. Belloni L, Allweiss L, Guerrieri F, et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012;122:529-37.
58. Uprichard SL, Wieland SF, Althage A, et al. Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proc Natl Acad Sci U S A 2003;100:1310-15. (Pubitemid 36183998)
59. Xu C, Guo H, Pan XB, et al. Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol 2010;84:9332-40.
60. Tang TJ, Kwekkeboom J, Mancham S, et al. Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection. J Hepatol 2005;43:45-52. (Pubitemid 40812351)
61. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7.
62. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49:1141-50.
63. Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010;52:1251-7.
64. Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011- a core group report. J Hepatol 2011;55:1121-31.
65. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010;52:454-61.
66. Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005;128:1890-7. (Pubitemid 40824700)
67. Wong DK, Yuen MF, Ngai VW, et al. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 2006;11:909-16. (Pubitemid 44736182)
68. Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010;51:1933-44.
69. Pollicino T, Raffa G, Santantonio T, et al. Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses. J Virol 2011;85:432-9.
70. Manesis EK, Papatheodoridis GV, Tiniakos DG, et al. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol 2011;55:61-8.
71. Qin Y, Tang X, Garcia T, et al. Hepatitis B virus genotype C isolates with wild-type core promoter sequence replicate less efficiently than genotype B isolates but possess higher virion secretion capacity. J Virol 2011;85:10167-77.
72. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172*mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008;48:88-98. (Pubitemid 351975534)
73. Ito K, Qin Y, Guarnieri M, et al. Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site. J Virol 2010;84:12850-61.
74. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t) ide analogues. Gastroenterology 2009;137:1593-608, e1-2.
75. Wieland SF, Guidotti LG, Chisari FV. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 2000;74:4165-73. (Pubitemid 30214422)
76. Wieland SF, Eustaquio A, Whitten-Bauer C, et al. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A 2005;102:9913-17. (Pubitemid 40993667)
77. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5:215-29. (Pubitemid 40364823)
78. Guidotti LG, Rochford R, Chung J, et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284:825-9. (Pubitemid 29291352)
79. Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003;77:68-76. (Pubitemid 36004947)
80. Dunn C, Peppa D, Khanna P, et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009;137:1289-300.
81. Wieland S, Thimme R, Purcell RH, et al. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 2004;101:6669-74. (Pubitemid 38586032)
82. Lucifora J, Durantel D, Testoni B, et al. Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology 2010;51:63-72.
83. Isogawa M, Robek MD, Furuichi Y, et al. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005;79:7269-72. (Pubitemid 40677357)
84. Wu J, Lu M, Meng Z, et al. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 2007;46:1769-78.
85. Boehme KW, Compton T. Innate sensing of viruses by toll-like receptors. J Virol 2004;78:7867-73. (Pubitemid 38944272)
86. Kimura K, Kakimi K, Wieland S, et al. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol 2002;76:10702-7. (Pubitemid 35176186)
87. Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol 2007;85:16-23. (Pubitemid 46067317)
88. Dunn C, Brunetto M, Reynolds G, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007;204:667-80. (Pubitemid 46457088)
89. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut. Published Online First: 9 December 2011. doi:10.1136/gutjnl- 2011-301073
90. Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect Dis 2002;2:43-50. (Pubitemid 36109305)
91. Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Invest 1997;99:1472-7. (Pubitemid 27163796)
92. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65-91. (Pubitemid 32368030)
93. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511. (Pubitemid 38931765)
94. Chen M, Sallberg M, Hughes J, et al. Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 2005;79:3016-27. (Pubitemid 40270581)
95. Locarnini S, Shaw T, Dean J, et al. Cellular response to conditional expression of the hepatitis B virus precore and core proteins in cultured hepatoma (Huh-7) cells. J Clin Virol 2005;32:113-21. (Pubitemid 40093961)
96. Visvanathan K, Skinner NA, Thompson AJ, et al. Regulation of toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007;45:102-10. (Pubitemid 46150869)
97. Frelin L, Wahlstrom T, Tucker AE, et al. A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection. J Virol 2009;83:1379-92.
98. Christen V, Duong F, Bernsmeier C, et al. Inhibition of alpha interferon signaling by hepatitis B virus. J Virol 2007;81:159-65. (Pubitemid 44975156)
99. Park IY, Sohn BH, Yu E, et al. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology 2007;132:1476-94. (Pubitemid 46627570)
100. Vivekanandan P, Daniel HD, Kannangai R, et al. Hepatitis B virus replication induces methylation of both host and viral DNA. J Virol 2010;84:4321-9.
101. Wei C, Ni C, Song T, et al. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol 2010;185:1158-68.
102. Xu Y, Hu Y, Shi B, et al. HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol 2009;46:2640-6.
103. Chen G, Lin W, Shen F, et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006;101:1797-803. (Pubitemid 44166589)
104. Bar-Yishay I, Shaul Y, Shlomai A. Hepatocyte metabolic signalling pathways and regulation of hepatitis B virus expression. Liver Int 2011;31:282-90.
105. Hajjou M, Norel R, Carver R, et al. cDNA microarray analysis of HBV transgenic mouse liver identifies genes in lipid biosynthetic and growth control pathways affected by HBV. J Med Virol 2005;77:57-65. (Pubitemid 41076477)
106. Kim KH, Shin HJ, Kim K, et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology 2007;132:1955-67. (Pubitemid 46677949)
107. Yang B, Bouchard MJ. The hepatitis B virus x protein elevates cytosolic calcium signals by modulating mitochondrial calcium uptake. J Virol 2012;86:313-27.
108. Zhang Z, Protzer U, Hu Z, et al. Inhibition of cellular proteasome activities enhances hepadnavirus replication in an HBX-dependent manner. J Virol 2004;78:4566-72. (Pubitemid 38501077)
109. Pollicino T, Belloni L, Raffa G, et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006;130:823-37. (Pubitemid 43374531)
110. Belloni L, Pollicino T, De Nicola F, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A 2009;106:19975-9.
111. Kim JW, Lee SH, Park YS, et al. Replicative activity of hepatitis B virus is negatively associated with methylation of covalently closed circular DNA in advanced hepatitis B virus infection. Intervirology 2011;54:316-25.
112. Liu WH, Yeh SH, Chen PJ. Role of microRNAs in hepatitis B virus replication and pathogenesis. Biochim Biophys Acta 2011;1809:678-85.
113. Thursz MR, Kwiatkowski D, Allsopp CE, et al. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995;332:1065-9.
114. Guo X, Zhang Y, Li J, et al. Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population. Hepatology 2011;53:422-8.
115. Deng G, Zhou G, Zhai Y, et al. Association of estrogen receptor alpha polymorphisms with susceptibility to chronic hepatitis B virus infection. Hepatology 2004;40:318-26. (Pubitemid 39062849)
116. Deng G, Zhou G, Zhang R, et al. Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers. Gastroenterology 2008;134:716-26.
117. Tacke F, Gehrke C, Luedde T, et al. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J Virol 2004;78:8524-35. (Pubitemid 39025118)
118. Ogata N, Miller RH, Ishak KG, et al. The complete nucleotide sequence of a pre-core mutant of hepatitis B virus implicated in fulminant hepatitis and its biological characterization in chimpanzees. Virology 1993;194:263-76.
119. Liu CJ, Chen BF, Chen PJ, et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis 2006;193:1258-65.
120. Raimondo G, Brunetto MR, Pontisso P, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 2006;43:100-7. (Pubitemid 43733596)
121. Jardi R, Rodriguez F, Buti M, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001;34:404-10. (Pubitemid 32702354)
122. Buti M, Homs M, Rodriguez-Frias F, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat 2011;18:434-42.